These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32389720)

  • 1. Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin.
    Derendorf H
    Int J Antimicrob Agents; 2020 Jun; 55(6):106007. PubMed ID: 32389720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect.
    Andreani J; Le Bideau M; Duflot I; Jardot P; Rolland C; Boxberger M; Wurtz N; Rolain JM; Colson P; La Scola B; Raoult D
    Microb Pathog; 2020 Aug; 145():104228. PubMed ID: 32344177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19.
    Norinder U; Tuck A; Norgren K; Munic Kos V
    Biomed Pharmacother; 2020 Oct; 130():110582. PubMed ID: 32763818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
    Fantini J; Chahinian H; Yahi N
    Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32862840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19.
    Kara E; Demirkan K; Unal S
    Int J Antimicrob Agents; 2020 Sep; 56(3):106123. PubMed ID: 32738307
    [No Abstract]   [Full Text] [Related]  

  • 6. Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome.
    Okour M; Al-Kofahi M; Austin D
    J Pharmacokinet Pharmacodyn; 2020 Jun; 47(3):187-188. PubMed ID: 32405664
    [No Abstract]   [Full Text] [Related]  

  • 7. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.
    Maisonnasse P; Guedj J; Contreras V; Behillil S; Solas C; Marlin R; Naninck T; Pizzorno A; Lemaitre J; Gonçalves A; Kahlaoui N; Terrier O; Fang RHT; Enouf V; Dereuddre-Bosquet N; Brisebarre A; Touret F; Chapon C; Hoen B; Lina B; Calatrava MR; van der Werf S; de Lamballerie X; Le Grand R
    Nature; 2020 Sep; 585(7826):584-587. PubMed ID: 32698191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy.
    Scherrmann JM
    AAPS J; 2020 Jun; 22(4):86. PubMed ID: 32533263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
    Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxychloroquine in Covid-19: Does the end justify the means?
    Yakoub-Agha I
    Curr Res Transl Med; 2020 Aug; 68(3):81-82. PubMed ID: 32340837
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling.
    Rowland Yeo K; Zhang M; Pan X; Ban Ke A; Jones HM; Wesche D; Almond LM
    Clin Pharmacol Ther; 2020 Nov; 108(5):976-984. PubMed ID: 32531808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU.
    Duška F; Waldauf P; Halačová M; Zvoníček V; Bala J; Balík M; Beneš J; Klementová O; Kozáková I; Kubricht V; Le Roy A; Vymazal T; Řehořová V; Černý V;
    Trials; 2020 Jul; 21(1):631. PubMed ID: 32641163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?
    Machiels JD; Bleeker-Rovers CP; Ter Heine R; Rahamat-Langendoen J; de Mast Q; Ten Oever J; Bousema T; van Crevel R; Wertheim HF
    Int J Antimicrob Agents; 2020 Jul; 56(1):106056. PubMed ID: 32674929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?
    Mégarbane B; Scherrmann JM
    J Clin Pharmacol; 2020 Jul; 60(7):808-814. PubMed ID: 32434282
    [No Abstract]   [Full Text] [Related]  

  • 15. The COVIRL-001 Trial: A multicentre, prospective, randomised trial comparing standard of care (SOC) alone, SOC plus hydroxychloroquine monotherapy or SOC plus a combination of hydroxychloroquine and azithromycin in the treatment of non- critical, SARS-CoV-2 PCR-positive population not requiring immediate resuscitation or ventilation but who have evidence of clinical decline: A structured summary of a study protocol for a randomised controlled trial.
    Feeney E; Wallace D; Cotter A; Tinago W; McCarthy C; Keane D; Hussain R; Alvarez Barco E; Doran P; Mallon P
    Trials; 2020 May; 21(1):430. PubMed ID: 32450915
    [No Abstract]   [Full Text] [Related]  

  • 16. [Hydroxychloroquine. Cardiology's viewpoint in times of coronavirus pandemic].
    Zaidel EJ; Wyss Quintana FS; Sosa Liprandi Á; Mendoza I; Márquez MF; Nuñez E; Barbosa M; Baranchuk A
    Medicina (B Aires); 2020; 80(3):271-274. PubMed ID: 32442941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.
    Molina JM; Delaugerre C; Le Goff J; Mela-Lima B; Ponscarme D; Goldwirt L; de Castro N
    Med Mal Infect; 2020 Jun; 50(4):384. PubMed ID: 32240719
    [No Abstract]   [Full Text] [Related]  

  • 18. Cancer Progression Is Linked to Increased Risk of Death Within 30 Days of COVID-19 Diagnosis.
    McDonald R
    Oncology (Williston Park); 2020 Jul; 34(7):249. PubMed ID: 32674206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
    Nina PB; Dash AP
    Indian J Public Health; 2020 Jun; 64(Supplement):S125-S127. PubMed ID: 32496241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The coronavirus outbreak could make it quicker and easier to trial drugs.
    Ledford H
    Nature; 2020 Jun; 582(7811):172. PubMed ID: 32504019
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.